Enliven Therapeutics is a pre-revenue clinical-stage biotech focused on precision oncology, with its balance sheet materially strengthened by a $445M equity raise in 2026Q2, lifting cash to $135.5M and total assets to $910.2M. The company's primary growth driv...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.49-26.6% vs -$0.39 | — vs — |
Q2 2026 May 7, 2026 | -$0.38+13.6% vs -$0.44 | — vs — |
Q2 2026 Mar 3, 2026 | -$0.48-14.3% vs -$0.42 | — vs $12,500 |
Q4 2025 Nov 12, 2025 | -$0.32+25.6% vs -$0.43 | — vs $8,330 |
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare ConferenceDate: Tuesday, Sept.
Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, funding operations into 2030 and the pivotal ENABLE-2 trial. ELVN-001 targets chronic myeloid leukemia as a selective ATP-competitive inhibitor, aiming for a differentiated, chronic-use profile in a sequential treatment paradigm. Phase 1 data show 61% MMR at 80 mg daily, with favorable safety and convenience for chronic administration, supporting potential in earlier-line CML settings.
BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in an oral and a poster presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting, taking place September 9-12, 2026, at the George R.
Benchmark ELVN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Enliven Therapeutics, Inc. (ELVN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $46.09 | $3.29B | -25.19 | — | — | -26.95% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $190.74 | $40.55B | -32.06 | — | — | -96.44% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $16.40 | $2.11B | 7.92 | 20.38% | 100.84% | 59% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — |
Enliven Therapeutics, Inc. (ELVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Enliven Therapeutics, Inc. (ELVN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 12, 2026·SEC
Jun 11, 2026·SEC
Get notified when ELVN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Enliven Therapeutics, Inc. (ELVN) stock FAQ — growth, dividends, profitability & financials explained
Enliven Therapeutics, Inc. (ELVN) reported a net loss of $105.9M for fiscal year 2025.
Enliven Therapeutics, Inc. (ELVN) has a return on equity (ROE) of -27.0%. Negative ROE indicates the company is unprofitable.
Enliven Therapeutics, Inc. (ELVN) had negative free cash flow of $67.0M in fiscal year 2025, likely due to heavy capital investments.
